LT4349369T - Vaisto biologinio įsisavinamumo pagerinimas taikant naltreksono terapiją - Google Patents

Vaisto biologinio įsisavinamumo pagerinimas taikant naltreksono terapiją

Info

Publication number: LT4349369T
Authority: LT; Lithuania
Prior art keywords: drug bioavailability; increasing drug; naltrexone therapy; naltrexone; therapy
Prior art date: 2010-12-03

Application number

LTEP23209711.3T

Other languages

English (en)

Inventor

Shawn Flanagan

Eduardo Dunayevich

Original Assignee

Nalpropion Pharmaceuticals Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-12-03

Filing date

2011-12-02

Publication date

2026-01-12

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46172304&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT4349369(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-12-02 Application filed by Nalpropion Pharmaceuticals Llc filed Critical Nalpropion Pharmaceuticals Llc

2026-01-12 Publication of LT4349369T publication Critical patent/LT4349369T/lt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M21/00—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Hematology (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Obesity (AREA)
Child & Adolescent Psychology (AREA)
Physics & Mathematics (AREA)
Acoustics & Sound (AREA)
Psychology (AREA)
Anesthesiology (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)

LTEP23209711.3T 2010-12-03 2011-12-02 Vaisto biologinio įsisavinamumo pagerinimas taikant naltreksono terapiją LT4349369T (lt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US41939510P	2010-12-03	2010-12-03

Publications (1)

Publication Number	Publication Date
LT4349369T true LT4349369T (lt)	2026-01-12

Family

ID=46172304

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
LTEP23209711.3T LT4349369T (lt)	2010-12-03	2011-12-02	Vaisto biologinio įsisavinamumo pagerinimas taikant naltreksono terapiją
LTEP21152314.7T LT3884947T (lt)	2010-12-03	2011-12-02	Augantis vaisto įsisavinimas taikant naltreksono terapiją
LTEP17156985.8T LT3222280T (lt)	2010-12-03	2011-12-02	Vaistų biologinio prieinamumo padidinimas naltreksono terapijoje
LTEP11845186.3T LT2646031T (lt)	2010-12-03	2011-12-02	Vaisto biologinio prieinamumo padidinimas naltreksono terapijos atveju

Family Applications After (3)

Application Number	Title	Priority Date	Filing Date
LTEP21152314.7T LT3884947T (lt)	2010-12-03	2011-12-02	Augantis vaisto įsisavinimas taikant naltreksono terapiją
LTEP17156985.8T LT3222280T (lt)	2010-12-03	2011-12-02	Vaistų biologinio prieinamumo padidinimas naltreksono terapijoje
LTEP11845186.3T LT2646031T (lt)	2010-12-03	2011-12-02	Vaisto biologinio prieinamumo padidinimas naltreksono terapijos atveju

Country Status (27)

Country	Link
US (1)	US20130245056A1 (lt)
EP (4)	EP2646031B9 (lt)
JP (5)	JP6008866B2 (lt)
KR (5)	KR20140035320A (lt)
CN (1)	CN103313711A (lt)
AR (2)	AR093182A1 (lt)
AU (2)	AU2011336304B2 (lt)
BR (1)	BR112013013390A2 (lt)
CA (2)	CA2819262C (lt)
CL (1)	CL2013001564A1 (lt)
CY (2)	CY1118968T1 (lt)
DK (4)	DK3884947T3 (lt)
ES (2)	ES2625527T3 (lt)
FI (2)	FI3884947T3 (lt)
HR (3)	HRP20170734T1 (lt)
HU (3)	HUE053831T2 (lt)
IL (3)	IL226504B (lt)
LT (4)	LT4349369T (lt)
MX (2)	MX384662B (lt)
PL (3)	PL3222280T3 (lt)
PT (4)	PT2646031T (lt)
RS (3)	RS65198B1 (lt)
RU (1)	RU2640561C2 (lt)
SI (3)	SI2646031T1 (lt)
SM (4)	SMT202500474T1 (lt)
TW (1)	TWI618536B (lt)
WO (1)	WO2012075459A1 (lt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4343948B2 (ja)	2003-04-29	2009-10-14	オレキシジェン・セラピューティクス・インコーポレーテッド	体重減少に影響を及ぼすための組成物
DK2135603T3 (da)	2005-11-22	2013-03-25	Orexigen Therapeutics Inc	Sammensætninger og fremgangsmåder til øgning af insulinsensitivitet
WO2007089318A2 (en) *	2005-11-23	2007-08-09	Orexigen Therapeutics, Inc.	Compositions and methods for reducing food cravings
CA2725930A1 (en)	2008-05-30	2009-12-30	Orexigen Therapeutics, Inc.	Methods for treating visceral fat conditions
EP2523557B1 (en)	2010-01-11	2019-09-25	Nalpropion Pharmaceuticals, Inc.	Methods of providing weight loss therapy in patients with major depression
SMT202500474T1 (it) *	2010-12-03	2026-01-12	Nalpropion Pharmaceuticals Llc	Aumento della biodisponibilità farmacologica nella terapia con naltrexone
EP4629257A3 (en)	2012-06-06	2025-12-10	Nalpropion Pharmaceuticals LLC	Composition for use in a method of treating overweight and obesity in patients with high cardiovascular risk
EP3253379A4 (en) *	2015-02-07	2018-10-10	Intas Pharmaceuticals Limited	Pharmaceutical composition for the treatment of obesity
CA3083850A1 (en) *	2017-03-28	2019-10-04	LDN Pharma Limited	An agent that increases the expression of the bcl2-associated agonist of cell death for the treatment of cancer
EP3482751A1 (en) *	2017-11-14	2019-05-15	LDN Pharma Limited	Cancer treatment
US12303604B1 (en)	2024-10-16	2025-05-20	Currax Pharmaceuticals Llc	Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10129265A1 (de) *	2001-06-18	2003-01-02	Hf Arzneimittelforsch Gmbh	Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie
US6972291B2 (en) *	2002-07-02	2005-12-06	Bernstein Richard K	Method for reducing food intake
EP1772147A2 (en) *	2003-03-17	2007-04-11	Japan Tobacco, Inc.	Method for increasing the oral bioavailability of S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]-2-methylpropanethioate
JP4343948B2 (ja) *	2003-04-29	2009-10-14	オレキシジェン・セラピューティクス・インコーポレーテッド	体重減少に影響を及ぼすための組成物
KR20080042092A (ko)	2005-07-27	2008-05-14	오렉시젠 세러퓨틱스 인크.	체중감량 조성물
US8921344B2 (en) *	2006-11-03	2014-12-30	Salix Pharmaceuticals, Inc.	Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
DK2135603T3 (da)	2005-11-22	2013-03-25	Orexigen Therapeutics Inc	Sammensætninger og fremgangsmåder til øgning af insulinsensitivitet
WO2007089318A2 (en)	2005-11-23	2007-08-09	Orexigen Therapeutics, Inc.	Compositions and methods for reducing food cravings
JP2009517393A (ja)	2005-11-28	2009-04-30	オレキシジェン・セラピューティクス・インコーポレーテッド	不安症の治療方法
US8916195B2 (en)	2006-06-05	2014-12-23	Orexigen Therapeutics, Inc.	Sustained release formulation of naltrexone
RU2445077C2 (ru) *	2006-06-19	2012-03-20	АЛФАРМА, Инк.	Фармацевтические композиции
KR101264789B1 (ko) *	2006-06-30	2013-05-15	엘지디스플레이 주식회사	횡전계 방식 액정표시장치용 어레이 기판과 그 제조방법
CA2693992C (en)	2006-07-20	2017-01-31	Somaxon Pharmaceuticals, Inc.	Methods of improving the pharmacokinetics of doxepin
TW200829235A (en)	2006-11-09	2008-07-16	Orexigen Therapeutics Inc	Methods for administering weight loss medications
DE602007005402D1 (de) *	2006-11-09	2010-04-29	Orexigen Therapeutics Inc	Mehrschichtige pharmazeutische formulierungen mit einer schnell auflösenden zwischenschicht
ES2851177T3 (es) *	2007-04-11	2021-09-03	Biomarin Pharm Inc	Tetrahidrobiopterina para el tratamiento de afecciones asociadas con niveles elevados de fenilalanina
DE102007036076A1 (de)	2007-08-01	2009-02-05	Bayer Healthcare Aktiengesellschaft	Dipeptoid-Produgs und ihre Verwendung
US8318813B2 (en) *	2007-09-13	2012-11-27	Lcs Group, Llc	Method of treating binge eating disorder
CA2725930A1 (en)	2008-05-30	2009-12-30	Orexigen Therapeutics, Inc.	Methods for treating visceral fat conditions
SMT202500474T1 (it) *	2010-12-03	2026-01-12	Nalpropion Pharmaceuticals Llc	Aumento della biodisponibilità farmacologica nella terapia con naltrexone

2011
- 2011-12-02 SM SM20250474T patent/SMT202500474T1/it unknown
- 2011-12-02 PL PL17156985T patent/PL3222280T3/pl unknown
- 2011-12-02 LT LTEP23209711.3T patent/LT4349369T/lt unknown
- 2011-12-02 SM SM20210227T patent/SMT202100227T1/it unknown
- 2011-12-02 EP EP11845186.3A patent/EP2646031B9/en active Active
- 2011-12-02 EP EP17156985.8A patent/EP3222280B1/en active Active
- 2011-12-02 DK DK21152314.7T patent/DK3884947T3/da active
- 2011-12-02 TW TW100144442A patent/TWI618536B/zh active
- 2011-12-02 BR BR112013013390A patent/BR112013013390A2/pt not_active Application Discontinuation
- 2011-12-02 US US13/991,137 patent/US20130245056A1/en not_active Abandoned
- 2011-12-02 AR ARP110104512A patent/AR093182A1/es not_active Application Discontinuation
- 2011-12-02 SI SI201131199A patent/SI2646031T1/sl unknown
- 2011-12-02 HR HRP20170734TT patent/HRP20170734T1/hr unknown
- 2011-12-02 ES ES11845186.3T patent/ES2625527T3/es active Active
- 2011-12-02 DK DK17156985.8T patent/DK3222280T3/da active
- 2011-12-02 MX MX2017013169A patent/MX384662B/es unknown
- 2011-12-02 KR KR1020137017317A patent/KR20140035320A/ko not_active Ceased
- 2011-12-02 LT LTEP21152314.7T patent/LT3884947T/lt unknown
- 2011-12-02 LT LTEP17156985.8T patent/LT3222280T/lt unknown
- 2011-12-02 DK DK11845186.3T patent/DK2646031T3/en active
- 2011-12-02 HU HUE17156985A patent/HUE053831T2/hu unknown
- 2011-12-02 SM SM20240038T patent/SMT202400038T1/it unknown
- 2011-12-02 SI SI201131967T patent/SI3222280T1/sl unknown
- 2011-12-02 PT PT118451863T patent/PT2646031T/pt unknown
- 2011-12-02 EP EP23209711.3A patent/EP4349369B1/en active Active
- 2011-12-02 HU HUE21152314A patent/HUE065852T2/hu unknown
- 2011-12-02 EP EP21152314.7A patent/EP3884947B1/en active Active
- 2011-12-02 RS RS20240196A patent/RS65198B1/sr unknown
- 2011-12-02 CA CA2819262A patent/CA2819262C/en active Active
- 2011-12-02 CN CN2011800638854A patent/CN103313711A/zh active Pending
- 2011-12-02 FI FIEP21152314.7T patent/FI3884947T3/fi active
- 2011-12-02 PT PT171569858T patent/PT3222280T/pt unknown
- 2011-12-02 RS RS20170491A patent/RS56014B1/sr unknown
- 2011-12-02 LT LTEP11845186.3T patent/LT2646031T/lt unknown
- 2011-12-02 SM SM20170232T patent/SMT201700232T1/it unknown
- 2011-12-02 HU HUE11845186A patent/HUE034393T2/en unknown
- 2011-12-02 FI FIEP23209711.3T patent/FI4349369T3/fi active
- 2011-12-02 CA CA3239386A patent/CA3239386A1/en active Pending
- 2011-12-02 DK DK23209711.3T patent/DK4349369T3/da active
- 2011-12-02 KR KR1020197014576A patent/KR102105857B1/ko active Active
- 2011-12-02 MX MX2013006071A patent/MX356801B/es active IP Right Grant
- 2011-12-02 PL PL21152314.7T patent/PL3884947T3/pl unknown
- 2011-12-02 ES ES17156985T patent/ES2866879T3/es active Active
- 2011-12-02 PL PL11845186T patent/PL2646031T3/pl unknown
- 2011-12-02 HR HRP20240115TT patent/HRP20240115T1/hr unknown
- 2011-12-02 WO PCT/US2011/063177 patent/WO2012075459A1/en not_active Ceased
- 2011-12-02 KR KR1020217015625A patent/KR102391511B1/ko active Active
- 2011-12-02 RU RU2013127423A patent/RU2640561C2/ru active
- 2011-12-02 KR KR1020207011510A patent/KR102258043B1/ko active Active
- 2011-12-02 JP JP2013542229A patent/JP6008866B2/ja active Active
- 2011-12-02 KR KR1020187016354A patent/KR101984500B1/ko active Active
- 2011-12-02 SI SI201132102T patent/SI3884947T1/sl unknown
- 2011-12-02 AU AU2011336304A patent/AU2011336304B2/en active Active
- 2011-12-02 RS RS20210469A patent/RS62149B1/sr unknown
- 2011-12-02 PT PT232097113T patent/PT4349369T/pt unknown
- 2011-12-02 PT PT211523147T patent/PT3884947T/pt unknown
2013
- 2013-05-23 IL IL226504A patent/IL226504B/en active IP Right Grant
- 2013-05-31 CL CL2013001564A patent/CL2013001564A1/es unknown
2016
- 2016-09-12 JP JP2016177391A patent/JP6456890B2/ja active Active
2017
- 2017-05-18 CY CY20171100524T patent/CY1118968T1/el unknown
- 2017-06-26 AU AU2017204309A patent/AU2017204309A1/en not_active Abandoned
2018
- 2018-12-19 JP JP2018237245A patent/JP7025319B2/ja active Active
2019
- 2019-11-21 IL IL270841A patent/IL270841A/en unknown
2020
- 2020-12-21 IL IL279626A patent/IL279626A/en unknown
2021
- 2021-04-19 HR HRP20210618TT patent/HRP20210618T1/hr unknown
- 2021-04-19 CY CY20211100340T patent/CY1124331T1/el unknown
- 2021-12-23 AR ARP210103655A patent/AR124500A2/es unknown
2022
- 2022-02-10 JP JP2022019546A patent/JP2022060331A/ja active Pending
2024
- 2024-03-27 JP JP2024051334A patent/JP2024071605A/ja active Pending

Also Published As

Publication number	Publication date
PT2646031T (pt)	2017-05-25
IL279626A (en)	2021-03-01
JP2019056004A (ja)	2019-04-11
EP3222280A1 (en)	2017-09-27
HUE053831T2 (hu)	2021-07-28
KR20200044158A (ko)	2020-04-28
JP7025319B2 (ja)	2022-02-24
PT3222280T (pt)	2021-04-22
PL2646031T3 (pl)	2017-08-31
RS56014B1 (sr)	2017-09-29
CY1118968T1 (el)	2018-01-10
EP2646031A1 (en)	2013-10-09
KR20180069089A (ko)	2018-06-22
HRP20210618T1 (hr)	2021-09-17
EP3222280B1 (en)	2021-01-20
CA2819262C (en)	2024-05-28
FI3884947T3 (fi)	2024-01-30
JP6008866B2 (ja)	2016-10-19
JP2022060331A (ja)	2022-04-14
WO2012075459A1 (en)	2012-06-07
DK3884947T3 (da)	2024-01-22
EP2646031B1 (en)	2017-02-22
LT2646031T (lt)	2017-06-26
PL3222280T3 (pl)	2021-11-29
MX356801B (es)	2018-06-13
AR093182A1 (es)	2015-05-27
RS65198B1 (sr)	2024-03-29
CY1124331T1 (el)	2022-07-22
IL226504B (en)	2021-01-31
RU2017144631A (ru)	2019-02-18
EP3884947B1 (en)	2023-11-15
SMT202400038T1 (it)	2024-03-13
CN103313711A (zh)	2013-09-18
SI3222280T1 (sl)	2021-11-30
AU2011336304B2 (en)	2017-03-30
RS62149B1 (sr)	2021-08-31
KR102258043B1 (ko)	2021-05-28
KR102391511B1 (ko)	2022-04-26
KR101984500B1 (ko)	2019-05-31
RU2640561C2 (ru)	2018-01-09
LT3222280T (lt)	2021-05-10
DK3222280T3 (da)	2021-04-19
KR102105857B1 (ko)	2020-05-04
HUE065852T2 (hu)	2024-06-28
TWI618536B (zh)	2018-03-21
EP4349369A3 (en)	2024-05-15
IL270841A (en)	2020-01-30
EP3884947A1 (en)	2021-09-29
JP2024071605A (ja)	2024-05-24
SI2646031T1 (sl)	2017-07-31
CA3239386A1 (en)	2012-06-07
PL3884947T3 (pl)	2024-05-06
EP2646031A4 (en)	2014-04-23
JP2016210809A (ja)	2016-12-15
JP6456890B2 (ja)	2019-01-23
LT3884947T (lt)	2024-03-12
TW201304780A (zh)	2013-02-01
KR20190058702A (ko)	2019-05-29
AU2017204309A1 (en)	2017-07-13
AU2011336304A1 (en)	2013-07-11
RU2013127423A (ru)	2015-01-10
KR20140035320A (ko)	2014-03-21
MX2013006071A (es)	2013-10-01
DK4349369T3 (da)	2025-12-22
DK2646031T3 (en)	2017-05-22
SMT202100227T1 (it)	2021-07-12
HRP20170734T1 (hr)	2017-08-11
US20130245056A1 (en)	2013-09-19
CL2013001564A1 (es)	2014-05-02
KR20210063473A (ko)	2021-06-01
ES2625527T9 (es)	2018-09-25
FI4349369T3 (fi)	2025-12-17
HUE034393T2 (en)	2018-02-28
EP2646031B9 (en)	2018-01-10
RU2017144631A3 (lt)	2021-04-13
SI3884947T1 (sl)	2024-06-28
JP2013544290A (ja)	2013-12-12
ES2625527T3 (es)	2017-07-19
HRP20240115T1 (hr)	2024-06-07
EP4349369A2 (en)	2024-04-10
EP4349369B1 (en)	2025-09-17
BR112013013390A2 (pt)	2016-09-06
CA2819262A1 (en)	2012-06-07
ES2866879T3 (es)	2021-10-20
PT3884947T (pt)	2024-02-16
MX384662B (es)	2025-03-14
SMT201700232T1 (it)	2017-07-18
AR124500A2 (es)	2023-04-05
PT4349369T (pt)	2025-12-17
SMT202500474T1 (it)	2026-01-12

Publication	Publication Date	Title
IL279626A (en)	2021-03-01	Increasing the bioavailability of a drug in treatment with naltrexone
GB2479953B (en)	2015-04-29	Drug delivery device
IL226245A0 (en)	2013-07-31	History
IL221007A (en)	2016-06-30	Pharmaceutical combinations for antiviral therapy
ZA201209197B (en)	2016-08-31	Drug delivery device
SG10202001055YA (en)	2020-04-29	Drug delivery device
PL2560624T3 (pl)	2019-01-31	Formulacja terapeutyczna do zmniejszania skutków ubocznych leku
GB201010193D0 (en)	2010-07-21	Medicinal use
EP2575887A4 (en)	2015-01-14	CONJUGATES OF OPTIMIZED MEDICINES
GB201017597D0 (en)	2010-12-01	Drug detection
ZA201208185B (en)	2014-03-26	Intravaginall drug delivery device
HRP20141173T1 (hr)	2015-01-30	Medikament koji sadrži miramistin
GB201016864D0 (en)	2010-11-17	Therapeutic methods
EP2626055A4 (en)	2014-04-16	ACTIVE RELEASE DEVICE
GB201019527D0 (en)	2010-12-29	Redox drug derivatives
GB201006112D0 (en)	2010-05-26	Redox drug derivatives
PL390434A1 (pl)	2011-08-16	Preparat leczniczy